Identification of Ferroptosis-Related Gene in Age-Related Macular Degeneration Using Machine Learning

Meijiang Zhu1, Jing Yu1

  • 1Tongji University School of Medicine, Shanghai Tenth People's Hospital, Shanghai, China.

PubMed
Abstract

Insights

Ferroptosis, a type of cell death, may drive age-related macular degeneration (AMD) progression. Genes SLC2A1 and FADS2 show potential as diagnostic markers and therapeutic targets for AMD.

Area of Science:

  • Ophthalmology
  • Cell Biology
  • Genetics

Background:

  • Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss, with dry AMD being the most common form.
  • Retinal pigment epithelium (RPE) cell death is a key factor in dry AMD pathogenesis.
  • Ferroptosis, a form of programmed cell death driven by iron accumulation and lipid peroxidation, is implicated in AMD.

Purpose of the Study:

  • To investigate the role of ferroptosis in the progression of age-related macular degeneration (AMD).
  • To identify potential diagnostic biomarkers and therapeutic targets for AMD based on ferroptosis-associated genes.

Main Methods:

  • Differential gene expression analysis of AMD and normal samples (GSE29801 dataset).
  • Intersection of differentially expressed genes (DEGs) with ferroptosis gene sets to identify DEFGs.
  • Machine learning for screening diagnostic genes, followed by Gene Set Enrichment Analysis (GSEA).
  • Validation of diagnostic gene expression in AMD ferroptosis models (in vivo and in vitro).

Main Results:

  • Identified 462 DEGs between normal and AMD samples.
  • Functional enrichment revealed involvement in extracellular matrix processes.
  • Pinpointed 10 differentially expressed ferroptosis-associated genes (DEFGs).
  • Five ferroptosis feature diagnostic genes identified: VEGFA, SLC2A1, HAMP, HSPB1, and FADS2.
  • Validated increased expression of SLC2A1 and FADS2 in an AMD ferroptosis model.

Conclusions:

  • Ferroptosis may contribute to the advancement of age-related macular degeneration (AMD).
  • SLC2A1 and FADS2 show promise as novel diagnostic biomarkers for AMD.
  • These genes also represent potential therapeutic targets for AMD treatment.